Plain-English translation of NCT06819917 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are looking for new blood-based biomarkers—measurable signs in your blood—that can help doctors detect and stage liver scarring (fibrosis) in people with non-alcoholic fatty liver disease. Right now, a liver biopsy (a needle procedure) is the gold standard for checking how much scarring you have, but it's invasive and carries risks. This study aims to develop simpler, safer blood tests that could do the same job.
Fatty liver disease is becoming very common worldwide, and some people develop more serious scarring and inflammation over time. Because early detection of scarring is so important for guiding treatment and predicting outcomes, doctors need better, non-invasive tools. This study will help create blood tests that could spare patients from needing a painful biopsy.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll be asked to come in for a blood draw after fasting (not eating for several hours beforehand). The researchers will collect your blood sample, which will be used to identify new biomarkers and test new ways of assessing liver scarring. Your existing biopsy results, fibroscan images, and other test results will also be reviewed as part of the study. There are no medications or procedures to undergo—it's a one-time or limited-visit sample collection study.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Denmark
Germany